[1223403-58-4]    

MFCD28902192

Synonyms : (R)-N-(5-((S)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; ARRY-470; LOXO-101

Applications : Larotrectinib is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). Larotrectinib medication is used to treat children and adults with advanced TRK fusion-positive solid tumours.

References : Doebele R. C. et al.: Cancer Discov., 5(10), 1049-57, 2015; Nagasubramanian R. et al.: Pediatr Blood Cancer 63(8), 1468-70, 2016; Kathryn G. et al.: Blood 128, 278, 2016; Doebele R. C. et al.: Cancer Discov., 5(10), 1049-57, 2015.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.